Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments?-Reference-Cited by-同舟云学术

Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments?

Published:2001-03 Issue:1 Volume:66 Page:73-81
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Fellowes Deborah,Fallowfield Lesley J,Saunders Christobel M,Houghton Joan

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.springerlink.com/index/pdf/10.1023/A:1010684903199

Reference55 articles.

1. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1(8319): 257-261, 1983

2. Jonat W: Luteinizing hormone-releasing hormone analogues-the rationale for adjuvant use in premenopausal women with early breast cancer. Br J Cancer 78(Supp 4): 5-8, 1998

3. Love RR, Cameron L, Connell BL, Leventhal H: Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151: 1842-1847, 1991

4. Ribeiro G, Swindell R: The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma-7-yr results. Eur J Cancer Clin Oncol 21(8): 897-900, 1985

5. Baum M, Houghton J, Riley DL, Melhuish PB: Cancer Research Campaign Adjuvant Breast Trial for Patients Under 50. Horm Res 32 Suppl: 1226-1229, 1989

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and application of a weighted change score to evaluate interventions for vasomotor symptoms in patients with breast cancer using regression trees: a cohort study;Breast Cancer Research and Treatment;2024-05-19

2. A study demonstrating users’ preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE® in patients with lung cancer;Frontiers in Oncology;2024-04-10

3. The Feasibility, Acceptability, and Effectiveness of Electronic Patient-Reported Outcome Symptom Monitoring for Immune Checkpoint Inhibitor Toxicities: A Systematic Review;JCO Clinical Cancer Informatics;2023-06

4. Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review;Journal of Breast Cancer;2023

5. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline;Annals of Oncology;2022-09